Literature DB >> 33197148

Clinical and transcriptional recovery profiles in pediatric and adult multiple sclerosis patients.

Shay Menascu1,2, Yulia Khavkin1, Rina Zilkha-Falb1, Mark Dolev1, David Magalashvili1, Anat Achiron1,2, Michael Gurevich1,2.   

Abstract

OBJECTIVE: To determine whether pediatric-onset multiple sclerosis (POMS) and adults-onset multiple sclerosis (AOMS) patients are different in initial disease severity and recovery and to investigate the associations with peripheral blood mononuclear cells (PBMCs) transcriptional profiles.
METHODS: Clinical and radiological severity of first and second relapses and 6-month recovery were analyzed in 2153 multiple sclerosis (MS) patients and compared between POMS (onset at 8-18years old) and AOMS (onset at 19-40 years old) patients. PBMCs transcriptomes of 15 POMS and 15 gender-matched AOMS patients were analyzed 6 months after the first relapse and compared to 55 age-matched healthy controls. Differentially Expressed Genes (DEGs) with a false discovery rate ≤ 10% were evaluated using the Partek software.
RESULTS: POMS had increased Expanded Disability Status Scale (EDSS) score at first and second relapses, higher brain gadolinium-enhancing T1-lesions volume at first relapse, and more complete recovery after both relapses compared to AOMS. POMS patients, who recovered completely from the first relapse, were characterized by 19 DEGs that were mainly related to suppression of antigen presentation. Six upstream regulators of these genes were differentially expressed between pediatric and adult healthy controls. POMS patients, who showed no recovery from the first relapse, were characterized by 28 DEGs that were mainly associated with B-cell activation. Five upstream regulators of these genes were differentially expressed between pediatric and adult healthy controls.
INTERPRETATION: POMS patients may have more severe first and second relapses than AOMS. However, most often, POMS have better recovery that may be attributed to PBMCs age-related transcriptional profiles associated with antigen presentation and B-cell activation.
© 2020 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.

Entities:  

Year:  2020        PMID: 33197148      PMCID: PMC7818128          DOI: 10.1002/acn3.51244

Source DB:  PubMed          Journal:  Ann Clin Transl Neurol        ISSN: 2328-9503            Impact factor:   4.511


  50 in total

Review 1.  Multiple Sclerosis Functional Composite.

Authors:  Serkan Demir
Journal:  Noro Psikiyatr Ars       Date:  2018       Impact factor: 1.339

Review 2.  Genetics of multiple sclerosis.

Authors:  D A Dyment; A D Sadovnick; G C Ebers; A D Sadnovich
Journal:  Hum Mol Genet       Date:  1997       Impact factor: 6.150

3.  Are initial demyelinating event recovery and time to second event under differential control?

Authors:  T West; M Wyatt; A High; A Bostrom; E Waubant
Journal:  Neurology       Date:  2006-09-12       Impact factor: 9.910

4.  Demographics of pediatric-onset multiple sclerosis in an MS center population from the Northeastern United States.

Authors:  T Chitnis; B Glanz; S Jaffin; B Healy
Journal:  Mult Scler       Date:  2009-03-19       Impact factor: 6.312

5.  Effect of relapses on development of residual deficit in multiple sclerosis.

Authors:  Fred D Lublin; Monika Baier; Gary Cutter
Journal:  Neurology       Date:  2003-12-09       Impact factor: 9.910

6.  Multiple sclerosis relapses: a multivariable analysis of residual disability determinants.

Authors:  M Vercellino; A Romagnolo; A Mattioda; S Masera; C Piacentino; A Merola; A Chiò; R Mutani; P Cavalla
Journal:  Acta Neurol Scand       Date:  2008-08-05       Impact factor: 3.209

7.  Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis.

Authors:  Mark P Gorman; Brian C Healy; Mariann Polgar-Turcsanyi; Tanuja Chitnis
Journal:  Arch Neurol       Date:  2009-01

8.  The HLA-DRB1 and HLA-DQB1 alleles are associated with multiple sclerosis disability progression in Slovak population.

Authors:  Daniel Čierny; Ján Lehotský; Ema Kantorová; Štefan Sivák; Juraj Javor; Egon Kurča; Dušan Dobrota; Jozef Michalik
Journal:  Neurol Res       Date:  2018-04-05       Impact factor: 2.448

9.  Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.

Authors:  Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2011-02       Impact factor: 10.422

10.  Relapse recovery: The forgotten variable in multiple sclerosis clinical trials.

Authors:  Orhun H Kantarci; Burcu Zeydan; Elizabeth J Atkinson; Brittani L Conway; Carmen Castrillo-Viguera; Moses Rodriguez
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2019-12-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.